RxDoctor Payments Data

Leroy Varney, MD

Family Medicine · Lancaster, OHNPI 1790756740

Payments from drug & device makers

$262in general payments, 2019–2025

Across 15 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Urovant Sciences Inc$49
  • Lundbeck LLC$49
  • Avanir Pharmaceuticals, Inc.$39
  • UCB, Inc.$31
  • Acadia Pharmaceuticals Inc$28
  • SK Life Science, Inc.$22
  • plus $44 from 3 others
$125in research payments, 2019–2025

Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$125

What the payments were for

  • Food & beverage$262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$262 in reported general payments places this provider in the 40th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$28,463
Medicare patients
141
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate14$51,904
XareltoRivaroxaban193$49,323
EliquisApixaban179$48,744
GemtesaVibegron160$40,870
Demeclocycline Hcl28$30,229
JanuviaSitagliptin Phosphate65$28,541
JardianceEmpagliflozin87$26,043
TrulicityDulaglutide26$25,606
LinzessLinaclotide38$21,878
RexultiBrexpiprazole21$19,281
NuedextaDextromethorphan Hbr/Quinidine25$18,934
Divalproex Sodium255$18,416
FarxigaDapagliflozin Propanediol51$17,138
Potassium Chloride589$16,564
Carbamazepine169$15,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$17$40,870160 claims
Avanir Pharmaceuticals, Inc.Nuedexta$39$18,93425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →